Biotechnology
Commented by Stefan Feulner on June 10th, 2025 | 07:05 CEST
Palantir, NetraMark, Qualcomm – Caution, buy signals!
Artificial intelligence is fundamentally changing the economy. It optimizes processes, reduces costs, and creates new business models. Its use in the healthcare and pharmaceutical sectors is currently developing particularly dynamically. Data-based decisions and personalized medicine are significantly increasing efficiency. According to experts, the global market for AI in healthcare could grow disproportionately in the coming years. Many AI companies are still in the early stages of their development.
Read
Commented by Fabian Lorenz on June 9th, 2025 | 07:15 CEST
BioNTech billion-dollar deal a template for BioNxt Solutions? Bayer shares recommended as a buy!
The billion-dollar deal between BioNTech and Bristol-Myers Squibb was a real bombshell and has revitalized the biotech industry. While analysts are raising their price targets for the German biotech high-flyer, there are also critical voices. Investors are also wondering where Big Pharma will strike next. One potential candidate for a partnership is BioNxt Solutions. The Company aims to simplify drug administration using oral dissolvable films, skin patches, and tablets. Clinical trials are about to begin on the development of its lead product for the easier treatment of multiple sclerosis, and a key patent has just been granted in Europe. Due to its low valuation and universal application possibilities, a complete takeover is also conceivable. And what is Bayer doing? Despite numerous legal proceedings, the stock is performing well in 2025. Analysts see further upside potential and have upgraded the stock.
Read
Commented by Armin Schulz on June 6th, 2025 | 07:00 CEST
The US healthcare revolution: How are Bayer, PanGenomic Health, and Pfizer positioned?
The US healthcare system is undergoing unprecedented change under Secretary Robert F. Kennedy Jr. Pharmaceutical giants are groaning under drastic price controls and regulatory upheaval, while digital healthcare pioneers are sensing unprecedented opportunities. This systemic shock is tearing down old power structures and catapulting agile players to the forefront – an explosive interplay of risk and opportunity. Those who understand the new rules of the game will discover lucrative prospects amid the chaos. Today, we take a look at Bayer, PanGenomic Health, and Pfizer to see who stands to benefit.
Read
Commented by Fabian Lorenz on June 3rd, 2025 | 07:20 CEST
A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark
Bombshell news from BioNTech. The Company has announced a collaboration for its cancer pipeline - billions in revenue are on the horizon. The stock has surged significantly. Are there other exciting buying opportunities in the biotech and pharma sectors right now? US politics have recently dampened industry sentiment. The Trump administration wants to lower drug prices. One potential beneficiary is NetraMark, as this AI gem helps industry cut development costs and timelines. In addition, takeover speculation could drive the stock in the second half of the year. And what is Bayer doing? The stock has outperformed the DAX in 2025. Are there reasons to consider buying?
Read
Commented by Fabian Lorenz on June 3rd, 2025 | 07:10 CEST
SHOCK for RENK, "BUY" rating for Novo Nordisk, and PanGenomic Health follows in the footsteps of Hims & Hers
Shock for RENK & Co.! Yesterday afternoon, news broke that the EU plans to tap into the billions in profits made by defense companies. After all, these companies are facing a golden age. The shares ended their record run yesterday. The alternative medicine and dietary supplements sector is currently experiencing a boom in the US. PanGenomic Health wants a piece of that multi-billion-dollar market. The newcomer is launching an AI-based app offering recommendations, a marketplace, and diagnostics. The rollout will begin this summer. Anyone who missed out on the 800% gains at Hims & Hers should take a look at this newcomer. Novo Nordisk is a core investment in the pharmaceutical sector. However, expectations for the blockbuster drug Ozempic were likely set too high. After the stock's crash, things are now looking better again.
Read
Commented by Armin Schulz on June 2nd, 2025 | 07:10 CEST
Bayer, Vidac Pharma, Evotec – Grab your share of the USD 866 billion oncology jackpot
Oncology is undergoing an unprecedented revolution. With a projected market volume of USD 866 billion by 2034 and annual growth of 11%, AI-driven diagnostics, personalized gene therapies, and precision medicine are driving this boom. Rising disease rates worldwide are fueling investment, while technological leaps are making therapies more effective and opening up high-return opportunities. Three players aim to leverage this explosive momentum for their profitable future: Bayer, Vidac Pharma, and Evotec.
Read
Commented by Fabian Lorenz on May 29th, 2025 | 07:10 CEST
Rheinmetall unstoppable! Evotec shorted! Sensational news at Vidac Pharma! And what is BioNTech doing?
Sensational news at Vidac Pharma. Last year's biotech highflyer has published strong results for its cancer drug. The share price rose by 5% yesterday. Does this mean the consolidation is over? Analysts certainly see potential for a multiplication in value. Rheinmetall shares have gained over 200% this year alone. Analysts are raising their price targets and continue to recommend buying. Operationally, a lot is happening at the defense company. Meanwhile, Evotec has run out of steam operationally. The stock has become a plaything for takeover speculators and short sellers — who will win? BioNTech also wants to win the fight against cancer. Will the stock gain new momentum in the coming days?
Read
Commented by Nico Popp on May 29th, 2025 | 07:00 CEST
The next AI revolution is being spearheaded by these hidden champions: Palantir, NetraMark, Roche
Are you still working the same way you did five years ago? Let's be honest: AI has changed a lot. The opportunities are enormous, especially in biotechnology. Already in 2024, one in four venture capital dollars for AI projects went to the healthcare sector, according to Silicon Valley Bank. Although around 80% of the industry already works with AI, there is a wide range of applications, with significant differences between experiments and groundbreaking innovations. We present three AI beneficiaries from the healthcare sector and explain how investors can profit.
Read
Commented by Nico Popp on May 28th, 2025 | 06:55 CEST
Smart innovations for strong returns: BioNTech, BioNxt Solutions, and Siemens Healthineers
For a new drug to hit the market, it has to outperform existing alternatives – so innovation is key for biotech companies. In medical technology, too, innovations must first and foremost benefit patients. However, research and development are expensive. We analyze how BioNTech, BioNxt Solutions, and Siemens Healthineers are driving innovation and what that means for investors.
Read
Commented by André Will-Laudien on May 27th, 2025 | 07:15 CEST
Up to 1500% with high tech and artificial intelligence – Incredible price movements at Evotec, NetraMark Holdings, and D-Wave
Artificial intelligence can now be found in all sectors of the economy. Search processes, validations, and historical comparisons now take place in a matter of seconds, and a dramatic leap in productivity is on the horizon. The capital markets have set themselves the task of evaluating these future processes. This is no easy task, as most topics cannot be viewed in isolation. Last week, renewed tariff threats led to a short-term price correction. These losses had to be offset yesterday, with political denials from the US sending share prices skyrocketing again. Under intense pressure, investors now have to decide whether investments promise short- or medium-term success. We use three examples to show how challenging this has become. Where are the opportunities and risks?
Read